Free Trial
NYSE:BHC

Bausch Health Cos (BHC) Stock Price, News & Analysis

Bausch Health Cos logo
$6.04 -0.01 (-0.08%)
As of 10:55 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Bausch Health Cos Stock (NYSE:BHC)

Advanced

Key Stats

Today's Range
$6.04
▼
$6.17
50-Day Range
$5.64
▼
$7.01
52-Week Range
$4.33
▼
$8.00
Volume
100,506 shs
Average Volume
2.49 million shs
Market Capitalization
$2.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Hold

Company Overview

Bausch Health Companies Inc. is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, branded and generic pharmaceuticals, over-the-counter products and medical devices across a range of therapeutic areas.

Its business includes Salix Pharmaceuticals, which focuses on gastrointestinal treatments; Ortho Dermatologics, which develops prescription therapies for dermatological conditions; and Solta Medical, which provides energy-based medical and aesthetic devices. Bausch Health also markets pharmaceutical products internationally through its diversified portfolio.

The company operates in North America, Europe, Latin America and other international markets. Bausch Health was formerly known as Valeant Pharmaceuticals International and adopted its current name in 2018. Thomas J. Appio serves as the company’s chief executive officer.

AI Generated. May Contain Errors.

Bausch Health Cos Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

BHC MarketRank™: 

Bausch Health Cos scored higher than 65% of companies evaluated by MarketBeat, and ranked 326th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bausch Health Cos has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 strong buy rating, no buy ratings, 5 hold ratings, and 1 sell rating.

  • Upside Potential

    Bausch Health Cos has a consensus price target of $8.00, representing about 30.6% upside from its current price of $6.13.

  • Amount of Analyst Coverage

    Bausch Health Cos has only been the subject of 4 research reports in the past 90 days.

  • Read more about Bausch Health Cos' stock forecast and price target.
  • Earnings Growth

    Earnings for Bausch Health Cos are expected to decrease by -7.59% in the coming year, from $4.35 to $4.02 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bausch Health Cos is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bausch Health Cos is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bausch Health Cos has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Bausch Health Cos' valuation and earnings.
  • Percentage of Shares Shorted

    2.91% of the float of Bausch Health Cos has been sold short.
  • Short Interest Ratio / Days to Cover

    Bausch Health Cos has a short interest ratio ("days to cover") of 3.06, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bausch Health Cos has recently increased by 4.96%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Bausch Health Cos does not currently pay a dividend.

  • Dividend Growth

    Bausch Health Cos does not have a long track record of dividend growth.

  • News Sentiment

    Bausch Health Cos has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Bausch Health Cos this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for BHC on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Bausch Health Cos to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bausch Health Cos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $258,894.00 in company stock.

  • Percentage Held by Insiders

    20.67% of the stock of Bausch Health Cos is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    78.65% of the stock of Bausch Health Cos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bausch Health Cos' insider trading history.
Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Cos and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BHC Stock News Headlines

Q3 EPS Estimate for Bausch Health Cos Raised by Analyst
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Bausch Health Companies Inc. (BHC)
See More Headlines

BHC Stock Analysis - Frequently Asked Questions

Bausch Health Cos' stock was trading at $6.95 at the beginning of the year. Since then, BHC shares have decreased by 11.9% and is now trading at $6.1250.

Bausch Health Cos Inc. (NYSE:BHC) announced its earnings results on Wednesday, July, 29th. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $0.96 by $0.30. The firm earned $2.83 billion during the quarter, compared to analysts' expectations of $2.59 billion. Bausch Health Cos had a negative trailing twelve-month return on equity of 561.95% and a negative net margin of 10.12%.
Read the conference call transcript
.

Bausch Health Cos' top institutional shareholders include Roxbury Financial LLC. Insiders that own company stock include John Paulson, Seana Carson, Aimee J Lenar and Frank D Lee.
View institutional ownership trends
.

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch Health Cos investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Tesla (TSLA), Bristol Myers Squibb (BMY) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
7/29/2026
Today
10/09/2026
Next Earnings (Estimated)
10/28/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:BHC
CIK
885590
Employees
20,300
Year Founded
1959

Price Target and Rating

High Price Target
$9.00
Low Price Target
$7.00
Potential Upside/Downside
+29.8%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.96)
Trailing P/E Ratio
N/A
Forward P/E Ratio
1.42
P/E Growth
N/A
Net Income
$157 million
Net Margins
-10.12%
Pretax Margin
-6.74%
Return on Equity
-561.95%
Return on Assets
6.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.44
Quick Ratio
1.08

Sales & Book Value

Annual Sales
$10.85 billion
Price / Sales
0.21
Cash Flow
$7.34 per share
Price / Cash Flow
0.84
Book Value
$1.02 per share
Price / Book
6.04

Miscellaneous

Outstanding Shares
374,383,000
Free Float
296,998,000
Market Cap
$2.31 billion
Optionable
Optionable
Beta
0.37

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:BHC) was last updated on 10/9/2026 by MarketBeat.com Staff.
From Our Partners